Trials / Unknown
UnknownNCT04258644
Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer
Efficacy and Safety of Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an interventional clinical trial to assess the efficacy and safety of camrelizumab in combination with apatinib mesylate, paclitaxel-albumin and S-1 for translational treatment of gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab+Apatinib+Paclitaxel-albumin+S-1 | Combination therapy of 4 drugs, 21 days for one cycle. |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
- First posted
- 2020-02-06
- Last updated
- 2020-02-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04258644. Inclusion in this directory is not an endorsement.